

## DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

**POLICY:** Infectious Disease – Prevyimis Drug Quantity Management Policy – Per Days

- Prevyimis™ (letermovir tablets – Merck Sharp & Dohme)

**REVIEW DATE:** 05/04/2022

---

### OVERVIEW

Prevymis is an antiviral drug indicated for the prophylaxis of **cytomegalovirus (CMV) infection** and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).<sup>1</sup>

### Dosing

The recommended dose of Prevyimis tablets is 480 mg once daily (QD).<sup>1</sup> Prevyimis is initiated between Day 0 and Day 28 post-transplantation (before or after engraftment), and continued through Day 100 post-transplantation.<sup>1,2</sup> The dose of Prevyimis should be adjusted to 240 mg QD when co-administered with cyclosporine.

### Off-Label Use

In retrospective analyses, Prevyimis has been found efficacious for prophylaxis of CMV in high-risk HSCT (e.g., patients with graft versus host disease). For this indication, Prevyimis dosing was extended beyond 100 days.<sup>3,4</sup> Prevyimis was also efficacious for secondary prophylaxis of CMV in HSCT patients, the median duration of secondary prophylaxis was 125 days.

### Availability

Prevymis tablets are available in the following strengths: 240 mg and 480 mg.<sup>1</sup> The tablets are packaged into a carton containing four dose packs, each containing a 7-count blister card for a total of 28 tablets, or into a carton containing two unit-dose 7-count blister cards for a total of 14 tablets. Prevyimis tablets should be stored in the original package until use.

### POLICY STATEMENT

This Drug Quantity Management program has been developed to prevent stockpiling and waste and to address potential order entry error of Prevyimis. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

**Automation:** None.

### Drug Quantity Limits

Product	Strength and Form	Maximum Quantity per 365 Days*
Prevymis™ (letermovir tablets)	240 mg tablets	112 tablets
	480 mg tablets	112 tablets

\*28 tablets per dispensing, maximum allows for 112 days of treatment (to accommodate packaging).

### CRITERIA

05/04/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

1. If the medication is being requested for the prophylaxis of cytomegalovirus in a high-risk hematopoietic stem cell transplant patient, approve for the requested treatment duration allowing 28 tablets per dispensing.

#### **REFERENCES**

1. Prevyomis™ [prescribing information]. Whitehouse Station, NJ: Merck Sharpe & Dohme; February 2021.
2. Marty FM, Ljungman RF, Cemaly J, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. *N Engl J Med.* 2017; 377:2433-44.
3. Bansal R, Gordillo CA, Abramova R, et al. Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease. *Transpl Infect Dis.* 2021;e123487.
4. Lin A, Maloy M, Su Y, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experienced. *Transpl Infect Dis.* 2019;21(6):e133187.